9th Annual New Therapeutics in Oncology: The Road to Personalized Medicine Featuring The Fenmore Lectureship and The Redlich Lectureship

Date & Location

Friday, November 13, 2020, 12:00 AM - Sunday, October 31, 2021, 11:59 PM

Target Audience

Specialties - Hematology, Internal Medicine, Oncology, Pain Management, Radiation Oncology, Surgery

Overview

This important educational activity will include a live virtual activity and a series of on-demand modules. The activity will provide guidance to front-line and oncology clinicians, nurses, physicians, pharmacists, nurse practitioners, physician assistants and pharmacists, with the most current information available about new agents in oncology and translating of the latest research to their patients. The content will cover drug and treatment updates with a focus on myeloma, gynecological malignancies, hematologic malignancies, sarcoma, bladder cancer and GI malignancies. The activity features a comprehensive review of new drugs approved in 2020 along with their mechanism of action, next generation CAR cell therapies and a keynote lecture outlining advances in immunotherapy. Next generation studies will also be addressed, and the activity will offer participants a module designed to provide insight into the latest advances in lung cancer treatment, including integration of new molecularly-targeted therapies and immunotherapy.

Live Webinar CME took place on November 13, 2020 and has concluded.
All of the recorded content can accessed by visiting the "Content & Tests" tab.

11:15 AM Exhibit Sponsored Forum/Workshops (Non-CME)

12:00 PM Introduction Moderator: Robert Figlin, MD

12:05 Keynote Presentation - Immunotherapy: Present and Future Antoni Ribas, MD (UCLA)

12:25 Q&A

12:35 Updates on New Therapeutics for Hematologic Malignancies Thomas Kipps, MD, PhD (UCSD)

1:00 PM Breakout Sessions

a. New Targets/Treatments - Monica Mita, MD; Razelle Kurzrock, MD; Alain Mita, MD; Omid Hamid, MD
b. Hematologics - Robert Vescio, MD; Thomas Kipps, MD, PhD; Justin Darrah, MD
c. Solid Tumors -Joyce O'Shaughnessy, MD; Ronald Natale, MD; Charles Forscher, MD; Scott Kopetz, MD; Jun Gong, MD; BJ Rimel, MD; Zach Zumsteg, MD

1:30 PM Adjourn

Objectives

Evaluate new, emerging and novel therapeutic agents, advances in care, and clinical trials data and apply relevant findings into the management of cancer patients
Develop personalized treatment plans for patients based upon an evaluation of efficacy and safety of current and newly approved agents and therapeutic options
Integrate appropriate strategies into clinical practice to optimize the management of patients with gynecologic malignancies to improve patient outcomes
Utilize AJCC or other appropriate staging in clinical practice, including appropriate prognostic indicators and evidence-based national guidelines for treatment planning
Anticipate the needs and issues of cancer survivors and develop an individualized wellness plan in partnership with cancer survivors, their families and the healthcare team

Registration

Physicians: $50.00
Industry: $100.00
Pharmacists: $25.00
Healthcare professional (nurses, fellows/residents, medical students): $0.00

Detailed instructions for accessing the on-demand content will be emailed after registration and payment are complete. Registration for this on demand CME course is non-refundable. Registered participants will be able to login and watch at their own pace on virtually any reliable internet-connected device (no downloading necessary).

The complete on-demand content is available for access now!

Modules Release/Expiration Dates:
Release Date: November 13, 2020
Expiration Date: October 31, 2021
Live Virtual Activity: November 13, 2020

Accreditation

Cedars-Sinai Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

For those participants engaging in the blended on-demand and live virtual activity, the credit designation is as follows:

Cedars-Sinai Medical Center designates this blended on-demand and live virtual activity for a maximum of 9.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For those participants engaging in the enduring activity only, the credit designation is as follows:

Cedars-Sinai Medical Center designates this enduring material for a maximum of 9.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-Physician Attendance
A certificate of participation will be provided to other health care professionals requesting credits. Participants should ensure in advance that their credentialing or licensing organization accepts AMA PRA Category 1 Credits™.

Credits

AMA PRA Category 1 Credit(s)™ (MD, DO) (9.00 hours), Non-Physician Attendance (RN, NP, PA and Others) (9.00 hours)

Keywords: ONLINE Virtual Activity

Faculty Member Information

Role in activity

Name of commercial interest/Nature of relationship

Robert A Figlin, MD

Steven Spielberg Family Chair in Hematology/Oncology; Director, Division of Hematology Oncology; Deputy Director
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai

Activity Course Director, Faculty

Consulting Fee-Pfizer, Inc.|Consulting Fee-Johnson and Johnson|Consulting Fee-Bristol-Myers Squibb

Razelle Kurzrock, MD

Distinguished Professor of Medicine, Associate Director, Clinical Science, Director, Center for Personalized Cancer Therapy, Leader, Experimental Therapeutics, Director, Rare Tumor Clinic, UC San Diego - Moores Cancer Center
UC San Diego Moores Cancer Center

Activity Course Director, Faculty

Fees for Non-CE Services Received Directly from a Commercial Interest or its Agent-Dr. Kurzrock receives research funding from Genentech, Merck Serono, Pfizer, Boehringer Ingelheim, TopAlliance, Takeda, Incyte, Debiopharm, Medimmune, Sequenom, Foundation Medicine, Konica Minolta, Grifols, Omniseq, and Guardant, as well as consultant and/or speaker fees and/or advisory board for X-Biotech, Neomed, Pfizer, Actuate Therapeutics, Roche, Turning Point Therapeutics, TD2/Volastra, Bicara Therapeutics, Inc., has an equity interest in IDbyDNA and CureMatch Inc, serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch.|Speakers Bureau-Roche|Ownership Interest-Equity interest in IDbyDNA and CureMatch Inc, serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch.

Alain Mita, MD

Co-Director, Experimental Therapeutics Program
Cedars-Sinai

Activity Course Director, Faculty

Speakers Bureau-Genentech, Inc.

Monica M. Mita, MD

Co-Director, Experimental Therapeutics Program
Cedars-Sinai

Activity Course Director, Faculty

Nothing to disclose

Justin Darrah, MD

Hematology/Oncology
Cedars-Sinai

Faculty

Consulting Fee-Morphosys|Contracted Research-Bristol-Myers Squibb

Charles Forscher, MD

Medical Director, Sarcoma Program
Cedars-Sinai

Faculty

Contracted Research-Karyopharm|Contracted Research-Deciphera

Jun Gong, MD

Medical Oncologist
Cedars-Sinai Medical Center

Faculty

Omid Hamid, MD

Chief, Translational Research and Immunotherapy; Director, Melanoma Therapeutics
Cedars-Sinai Marina Del Rey Hospital

Faculty

Advisory Board-Aduro, Akeso, Amgen, Array, Beigene, BMS, Genentech, GSK, Immunocore, Incyte, Janssen, Merck, Nextcure, Sanofi Regeneron, Seattle Genetics, Tempus, Zelluna |Speakers Bureau-Array Pfizer, BMS, Novartis, Sanofi Regeneron |Contracted Research-Contracted Research for Institution-Arcus, Aduro, Akeso, Amgen, Array, BMS, CytomX, Exelixis, Genentech, GSK, Immunocore, Incyte, Iovance, Merck, Moderna, Merck-Serono, NextCure, Novartis, Sanofi Regeneron, Seattle Genetics, Torque, Zelluna

Thomas Kipps, MD, PhD

Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research
UC San Diego School of Medicine

Faculty

Scott Kopetz, MD, PhD

Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center,

Faculty

Ronald B. Natale, MD

Medical Director, Clinical Lung Cancer Program
Cedars-Sinai Medical Center

Faculty

Consulting Fee-AstraZeneca|Contracted Research-AbbVie, G1 Therapeutics, Minneamrita Therapeutics, Pfizer, Rgenix, Salmedix |Spouse - Sr. MSL-AstraZeneca

Joyce O'Shaughnessy, MD

Faculty

Karen Reckamp, MD

Director, Medical Oncology
Cedars-Sinai

Faculty

Antoni Ribas, MD, PhD

Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology
David Geffen School of Medicine at UCLA

Faculty

Consulting Fee-AstraZeneca|Consulting Fee-Merck and Company, Inc.|Consulting Fee-Sanofi-Aventis

Bobbie Rimel, MD

Assistant Professor, Obstetrics and Gynecology
Cedars-Sinai

Faculty

Consulting Fee-Genentech, Inc.|Consulting Fee-AstraZeneca|Consulting Fee-Tesaro|Consulting Fee-Clovis|Consulting Fee-Deep6AI

Robert Vescio, MD

Medical Director, Multiple Myeloma and Amyloidosis Program in the Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai

Faculty

Speakers Bureau-Amgen, Glaxo Smith Klein, Karyopharm, Takeda

Zachary Zumsteg, MD

Assistant Professor, Radiation Oncology
Cedars-Sinai

Faculty

Contracted Research-Janssen

Hilary Lachoff, RN
Cedars-Sinai

Reviewer (content)

Nothing to disclose

Bethany Wendel, RN
Clinical Research Nurse
Cedars-Sinai Medical Center

Reviewer (content)

Nothing to disclose

Please see below for where and how to access course materials, including webinar access links, schedule, syllabus (slides and recordings), exhibits and evaluation. Some materials require log-in to the CME Portal or other system as noted.

How do I log-in to the CME Portal?

Click Sign In in the Menu Bar. Your log-in details can found in the reminder email for the activity. If you do not remember your password, click on "Forgot Your Password?" on the Sign In page.

How do I access the Live Virtual Activity?

Activity registrants will receive an email with the specific log-in instructions for Zoom entitled "Virtual Activity Instructions" from Cedars-Sinai CME <cme@cshs.org>. Please be sure to check your SPAM.

In addition, you can access the specific log-in instructions by logging in to the CME Portal, clicking the specific activity and selecting "Content and Tests".

Please note you will need access to a computer/device to run Zoom, Wi-Fi/internet, and audio to achieve the maximum learning experience. This Zoom information is only for registered attendees and should not be shared. Additional information on Zoom system requirements can be found here.

How do I the visit the Exhibits/Virtual Exhibitor Sessions?

Activity registrants will receive an email with instructions on how to access any virtual exhibitor sessions from Cedars-Sinai CME <cme@cshs.org>. Please be sure to check your SPAM.

In addition, you can find the exhibitor information on the Schedule and Sponsors/Exhibitors tabs for the activity in the CMEPortal. Any specific log-in instructions will be included on these pages. To ensure compliance with ACCME policies, exhibiting must occur separate from the CME activity.

How do I access the Slides and Activity Recordings After the Live Virtual Activity?

Activity registrants can access the slides and activity recordings by logging in to the CME Portal, clicking the specific activity and selecting "Content and Tests".

Please be aware that you are not authorized to record, copy or share content in any manner.

How do I complete an Evaluation and Claim CME Credit?

Log-in to the CME Portal, click the "Content and Tests" tab in the activity. Once you have completed all of the modules, click on the module "9th Annual New Therapeutics in Oncology Evaluation and Post-Test".

Your certificate will be available after you complete the evaluation.

Exhibitor Packages